Lowest Price Guaranteed From USD 4,899
Published
April 2020
Pages
206
View Count
11584
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
The endocannabinoid system targeted therapeutics market is projected to be worth $5.4 billion by 2030, representing a CAGR of over 28%.Chronic conditions, such as arthritis, cancer, diabetes, and heart disease are known to affect approximately 133 million Americans, representing over 40% of the total US population. This number is projected to grow to 157 million by the end of 2020. In addition, nearly 20 million Americans are estimated to suffer from some form of neurological disorder. Such conditions are generally characterized by a variety of complex symptoms, such as seizures, chronic pain and sleep disorders, for which medical science has not yet been able to identify an underlying cause. Drugs that offer symptomatic relief are the only treatment option currently available for such conditions. Traditionally, the go-to option has been opioids. However, this class of drugs has a high propensity of being abused. Moreover, there is a substantial body of evidence that proves that the long-term use of opioids leads to addiction, and eventually results in secondary substance use disorders. Cannabis has been shown to have properties similar to that of opioids, offering relief from a wide range of clinical symptoms. On the other hand, owing to its strong psychoactive properties, it is widely used as a recreational drug. As a result, there are stringent policies regulating the use of this substance, worldwide.
Over time, extensive R&D on the potential health benefits of cannabis, have enabled medical researchers to identify a number of pharmacologically active ingredients that offer clinical benefit, minus the addictive properties of the crude substance. Presently, cannabinoid derivatives, such as cannabidiol and cannabidivarin, have garnered the attention of the scientific community and are being investigated in mainstream clinical research initiatives. These molecules have been shown to modulate the endocannabinoid signaling system, primarily interacting with the CB1 and CB2 receptors. In fact, in 1985, the first synthetic cannabinoid drug, MARINOL®, was approved by the US FDA, for the treatment of nausea and vomiting, induced with chemotherapy. Recently, in 2018, EPIDIOLEX®, another cannabinoid derivative, was granted marketing authorization to be used to treat seizures associated with Lennox-Gastaut syndrome, or Dravet syndrome. Currently, there are several stakeholders in the pharmaceutical industry actively engaged in efforts to develop leads, derived from the Cannabis plant, as drugs to offer symptomatic relief across a diverse range of therapeutic areas. Of late, there has been substantial partnering activity in this field, as researchers / developers strive to forge strategic alliances, mostly to establish legitimate supply chains for raw material procurement, in order to support further research. Moreover, multiple start-ups, with backing from interested investors, have been established. As pioneers in this domain continue to achieve proof-of-concept, concerning the clinical benefits of this upcoming class of pharmacological molecules, we believe that this niche market is likely to witness substantial growth.
The “Endocannabinoid System Targeted Therapeutics Market, 2020-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of endocannabinoid system targeting drugs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:
One of the key objectives of the report was to estimate the existing market size and the future opportunity for endocannabinoid system targeted therapeutics, over the next decade. Based on multiple parameters, such as target patient population, likely adoption and the annual treatment cost, we have provided informed estimates on the evolution of endocannabinoid system targeted therapeutics market for the period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] key target receptors (CB1, CB2, and others) [B] different target therapeutic areas (autoimmune disorders, genetic disorders, neurological disorders and pain disorders) [C] routes of administration (oral and inhalation) and [D] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in the report were also influenced by discussions held with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order):
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the state of the market for endocannabinoid system targeted therapeutics, in the short-midterm and long term.
Chapter 3 provides a general overview of endocannabinoid system, including information on the key target receptors involved, role of cannabis-based therapies and their historical evolution. The chapter lays emphasis on the different target therapeutic areas / affiliated symptoms that can be potentially treated with endocannabinoid system targeted therapeutics. It also includes a discussion on the regulations and need for legalization of cannabis, the various challenges related to this intervention and highlights its future perspectives.
Chapter 4 includes information on more than 180 cannabis-based development programs that are either approved or being developed across different stages (clinical and preclinical / discovery) for the treatment of various therapeutic areas. It features a comprehensive analysis of marketed / pipeline molecules, highlighting, phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, route of administration (oral, topical, sublingual, oromucosal, inhalation and others), target receptor(s) (CB1, CB2, TRPV-1 and others) and target therapeutic area (s). In addition, the chapter provides information on drug developer(s), highlighting year of their establishment, location of headquarters and employee strength.
Chapter 5 provides detailed profiles of the drug developers having multiple drug development programs in their portfolio. Each profile features a brief overview of the company, its financial information (if available), product portfolio, recent developments and an informed future outlook.
Chapter 6 provides an analysis of nearly 600 grants that were awarded to research institutes engaged in endocannabinoid system targeted therapeutics related projects, in the period between 2016 and 2020 (till January) based on the important parameters associated with grants, such as the year of grant award, amount awarded, administration institute center, funding institute center, support period, type of grant application, purpose of grant award, grant mechanism, responsible study section, prominent program officers, and type of recipient organizations.
Chapter 7 features an elaborate analysis and discussion on the various collaborations and partnerships that have been inked amongst stakeholders in this domain, since 2016. It includes a brief description of various types of partnership models (namely acquisitions, licensing agreements, product development and commercialization agreements, research agreements, clinical trial agreements, joint venture agreements and other agreements) that have been adopted by stakeholders in this domain.
Chapter 8 features a detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2016-2020, based on parameters, such as key value drivers, year of acquisition, type of acquisition, geographical location of the acquirer and the acquired company, and financial details of the deal (if available). In addition, the chapter evaluates the deal multiples of acquisitions specifically focused on endocannabinoid system targeted therapeutics, analyzing them based on a number of parameters, namely annual revenues, number of employees and the experience of the acquired company. Moreover, it presents a schematic world map representation of the geographical distribution of this activity, highlighting inter- and intracontinental deals.
Chapter 9 features an insightful chessboard analysis highlighting the most popular drug development strategies / paths adopted by various drug developers (with clinical candidates) engaged in this domain in order to accelerate the progress of their lead drug candidates.
Chapter 10 features a detailed market forecast analysis, highlighting the likely growth of endocannabinoid system targeted therapeutics till the year 2030. We have provided inputs on the likely distribution of the opportunity based on different target therapeutic area (autoimmune disorders, genetic disorders, neurological disorders and pain disorders), key target receptors (CB1, CB2, and others), routes of administration (oral and inhalation), and key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
Chapter 11 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the endocannabinoid system targeted therapeutics industry.
Chapter 12 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented a brief overview of the companies and details of our conversations held with Oludare Odumosu (Managing Director, Zelira Therapeutics US), Andrea Small-Howard (Chief Scientific Officer, GB Sciences), Steeve Néron (Chief Operating Officer, Tetra Bio-Pharma), Stephen Dahmer (Chief Medical Officer, Vireo Health).
Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 14 is an appendix, which contains a list of companies and organizations mentioned in this report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Neuropharmacology and Working Mechanism of the Endocannabinoid System
3.3. Potential Therapeutic Applications of Cannabinoids
3.4. Legal Aspects and Regulations
3.5. Existing Challenges
3.6. Future of Cannabinoid-based Therapies
4. MARKET LANDSCAPE: ENDOCANNABINOID SYSTEM TARGETED THERAPEUTICS
4.1. Chapter Overview
4.2. Drugs Targeting Endocannabinoid System: Marketed and Development Pipeline
4.3. Endocannabinoid System Targeted Therapeutics: Pipeline Analysis
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Target Therapeutic Area
4.3.3. Analysis by Route of Administration
4.3.4. Analysis by Dosing Frequency
4.3.5. Analysis by Target Receptor
4.3.6. Grid Analysis: Distribution by Phase of Development, Target Therapeutic Area and Target Receptor
4.4. Endocannabinoid System Targeted Therapeutics: List of Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size and Geographical Location
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. GW Pharmaceuticals
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Endocannabinoid Targeting Therapeutics Portfolio
5.2.3.1. Marketed / Clinical-stage Molecules
5.2.4. Recent Developments and Future Outlook
5.3. Corbus Pharmaceuticals
5.3.1. Company Overview
5.3.2. Endocannabinoid Targeting Therapeutics Portfolio
5.3.2.1. Marketed / Clinical-stage Molecules
5.3.2.2. Pre-Clinical-stage Molecules
5.3.3. Recent Developments and Future Outlook
5.4. Tilray
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Endocannabinoid Targeting Therapeutics Portfolio
5.4.3.1. Marketed / Clinical-stage Molecules
5.4.4. Recent Developments and Future Outlook
5.5. Tetra Bio-Pharma
5.5.1. Company Overview
5.5.2. Endocannabinoid Targeting Therapeutics Portfolio
5.5.2.1. Marketed / Clinical-stage Molecules
5.5.3. Recent Developments and Future Outlook
5.6. Botanix Pharmaceuticals
5.6.1. Company Overview
5.6.2. Endocannabinoid Targeting Therapeutics Portfolio
5.6.2.1. Marketed / Clinical-stage Molecules
5.6.2.2. Pre-Clinical-stage Molecules
5.6.3. Recent Developments and Future Outlook
5.7. Kalytera Therapeutics
5.7.1. Company Overview
5.7.2. Endocannabinoid Targeting Therapeutics Portfolio
5.7.2.1. Marketed / Clinical-stage Molecules
5.7.2.2. Pre-Clinical-stage Molecules
5.7.3. Recent Developments and Future Outlook
5.8. Therapix Biosciences
5.8.1. Company Overview
5.8.2. Endocannabinoid Targeting Therapeutics Portfolio
5.8.2.1. Marketed / Clinical-stage Molecules
5.8.2.2. Pre-Clinical-stage Molecules
5.8.3. Recent Developments and Future Outlook
5.9. Avicanna
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Endocannabinoid Targeting Therapeutics Portfolio
5.9.3.1. Marketed / Clinical-stage Molecules
5.9.3.2. Pre-Clinical-stage Molecules
5.9.4. Recent Developments and Future Outlook
5.10. GB Sciences
5.10.1. Company Overview
5.10.2. Financial Information
5.10.3. Endocannabinoid Targeting Therapeutics Portfolio
5.10.3.1. Pre-Clinical-stage Molecules
5.10.4. Recent Developments and Future Outlook
5.11. Echo Pharmaceuticals
5.11.1. Company Overview
5.11.2. Endocannabinoid Targeting Therapeutics Portfolio
5.11.2.1. Endocannabinoid Targeting Therapeutics Portfolio
5.11.2.2. Pre-Clinical-stage Molecules
6. ACADEMIC GRANTS ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Endocannabinoid System Targeted Therapeutics: Academic Grant Analysis
6.3.1. Analysis by Year of Grant Award
6.3.2. Analysis by Amount Awarded
6.3.3. Analysis by Administering Institute Center
6.3.4. Analysis by Funding Institute Center
6.3.5. Analysis by Support Period
6.3.6. Analysis by Funding Institute Center and Support Period
6.3.7. Analysis by Type of Grant Application
6.3.8. Analysis by Purpose of Grant Award
6.3.9. Analysis by Activity Code
6.3.10. Word Cloud Analysis: Emerging Focus Areas
6.3.11. Analysis by Study Section Involved
6.3.12. Popular NIH Departments: Analysis by Number of Grants
6.3.13. Analysis by Types of Recipient Organizations
6.3.14. Prominent Program Officers: Analysis by Number of Grants
6.3.15. Popular Recipient Organizations: Analysis by Number of Grants
6.3.16. Regional Distribution of Recipient Organizations
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Endocannabinoid Targeted Therapeutics: List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Type of Partnership and Type of Partner
7.3.4. Analysis by Year of Partnership and Type of Partner
7.3.5. Most Active Players: Analysis by Number of Partnerships
7.3.6. Regional Analysis
7.3.7. Intercontinental and Intracontinental Agreements
8. MERGERS AND ACQUISITIONS
8.1. Chapter Overview
8.2. Merger and Acquisition Models
8.3. Endocannabinoid Targeted Therapeutics: Mergers and Acquisitions
8.3.1. Analysis by Year of Mergers and Acquisitions
8.3.2. Analysis by Type of Mergers and Acquisitions
8.3.3. Continent-wise Distribution
8.3.4. Country-wise Distribution
8.3.5. Analysis by Key Value Drivers
8.3.6. Analysis by Key Value Drivers and Year of Acquisition
8.3.7. Key Value Drivers
8.3.8. Valuation Analysis: Acquisition Deal Multiples
9. DRUG DEVELOPMENT STRATEGY ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Strategies Adopted for Late-Stage Drug Candidates
9.3.1. EPIDIOLEX
9.3.2. CannEpil
9.3.3. Lenabasum
9.3.4. CAUMZ
9.3.5. CBD Oil
9.4. Concluding Remarks
10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Global Endocannabinoid Targeted Therapeutics Market, 2020-2030
10.4. Global Endocannabinoid Targeted Therapeutics Market: Individual Product Sales Forecasts
10.4.1. EPIDIOLEX (GW Pharmaceuticals)
10.4.1.1. Target Patient Population
10.4.1.2. Sales Forecast
10.4.2. CannEpil (MGC Pharmaceuticals)
10.4.2.1. Target Patient Population
10.4.2.2. Sales Forecast
10.4.3. GWP42003-P (GW Pharmaceuticals)
10.4.3.1. Target Patient Population
10.4.3.2. Sales Forecast
10.4.4. Lenabasum (Corbus Pharmaceuticals)
10.4.4.1. Target Patient Population
10.4.4.2. Sales Forecast
10.4.5. PPP011 (Tetra Bio-Pharma)
10.4.5.1. Target Patient Population
10.4.5.2. Sales Forecast
10.5. Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Target Receptor, 2025 and 2030
10.5.1. Global Endocannabinoid System Targeted Therapeutics Market for CB1 and CB2 Receptor Targeted Therapies, 2021-2030
10.5.2. Global Endocannabinoid System Targeted Therapeutics Market for CB2 Receptor Targeted Therapies, 2022-2030
10.5.3. Global Endocannabinoid System Targeted Therapeutics Market for Other Receptor Targeted Therapies, 2022-2030
10.6. Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Region, 2025 and 2030
10.6.1. Endocannabinoid System Targeted Therapeutics Market in the US, 2020-2030
10.6.2. Endocannabinoid System Targeted Therapeutics Market in the UK, 2020-2030
10.6.3. Endocannabinoid System Targeted Therapeutics Market in Germany, 2020-2030
10.6.4. Endocannabinoid System Targeted Therapeutics Market in France, 2020-2030
10.6.5. Endocannabinoid System Targeted Therapeutics Market in Italy, 2020-2030
10.6.6. Endocannabinoid System Targeted Therapeutics Market in Spain, 2020-2030
10.6.7. Endocannabinoid System Targeted Therapeutics Market in Japan, 2022-2030
10.6.8. Endocannabinoid System Targeted Therapeutics Market in Australia, 2020-2030
10.7. Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Target Therapeutic Area, 2025 and 2030
10.7.1. Global Endocannabinoid System Targeted Therapeutics Market for Autoimmune Diseases, 2022-2030
10.7.2. Global Endocannabinoid System Targeted Therapeutics Market for Cancer, 2022-2030
10.7.3. Global Endocannabinoid System Targeted Therapeutics Market for Inflammatory Diseases, 2022-2030
10.7.4. Global Endocannabinoid System Targeted Therapeutics Market for Genetic Disorders, 2021-2030
10.7.5. Global Endocannabinoid System Targeted Therapeutics Market for Neurological Disorders, 2020-2030
10.8. Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Route of Administration, 2025 and 2030
10.8.1. Global Endocannabinoid System Targeted Therapeutics Market for Oral Therapies, 2020-2030
10.8.5. Global Endocannabinoid System Targeted Therapeutics Market for Inhalation Therapies, 2022-2030
11. CONCLUDING REMARKS
12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2 Zelira Therapeutics US
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Oludare Odumosu, Chief Executive Officer
12.3. GB Sciences
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Andrea Small-Howard, Chief Scientific Officer
12.4. Tetra Bio-Pharma
12.4.1. Company Snapshot
12.4.2. Interview Transcript: Steeve Néron, Chief Operating Officer
12.5 Vireo Health
12.5.1. Company Snapshot
12.5.2. Interview Transcript: Stephen Dahmer, Chief Medical Officer
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Medical Cannabis: Historical Timeline
Figure 3.2 Cannabinoid Receptors: Distribution in Human Body
Figure 3.3 Endocannabinoids: Potential Therapeutic Areas
Figure 3.4 Medical Cannabis: Legal Landscape
Figure 3.5 Cannabis Legalization: Existing Challenges
Figure 3.6 Cannabis: Need for Legalization
Figure 4.1 Endocannabinoid System Targeted Therapeutics: Distribution by Phase of Development
Figure 4.2 Endocannabinoid System Targeted Therapeutics: Distribution by Target Therapeutic Area
Figure 4.3 Endocannabinoid System Targeted Therapeutics: Distribution by Target Therapeutic Area and Phase of Development
Figure 4.4 Endocannabinoid System Targeted Therapeutics: Distribution by Route of Administration
Figure 4.5 Endocannabinoid System Targeted Therapeutics: Distribution by Dosing Frequency
Figure 4.6 Endocannabinoid System Targeted Therapeutics: Distribution by Target Receptor
Figure 4.7 Endocannabinoid System Targeted Therapeutics: Distribution by Phase of Development, Target Therapeutic Area and Target Receptor
Figure 4.8 Endocannabinoid System Targeted Therapeutics: Distribution by Year of Establishment
Figure 4.9 Leading Developers: Distribution by Number of Therapies for Targeting Endocannabinoid System
Figure 4.10 Endocannabinoid System Targeted Therapeutics: Distribution Company Size and Geographical Location
Figure 4.11 World Map Representation: Distribution by Geography
Figure 5.1 GW Pharmaceuticals: Annual Revenues, 2015-2019 (USD Million)
Figure 5.2 Tilray: Annual Revenues, 2016- 2019 (USD Million)
Figure 5.3 Avicanna: Annual Revenues, 2017- 9M 2019 (USD Million)
Figure 5.4 GB Sciences: Annual Revenues, 2018- 2019 (USD Million)
Figure 6.1 Grant Analysis: Cumulative Trend by Year of Award, 2016-2020
Figure 6.2 Grant Analysis: Cumulative Distribution by Amount Awarded, 2016-2019 (USD Million)
Figure 6.3 Grant Analysis: Distribution by Administering Institute Center
Figure 6.4 Grant Analysis: Distribution by Funding Institute Center
Figure 6.5 Grant Analysis: Distribution by Support Period
Figure 6.6 Grant Analysis: Distribution by Funding Institute Center and Support Period
Figure 6.7 Grant Analysis: Distribution by Type of Grant Application
Figure 6.8 Grant Analysis: Distribution by Purpose of Grant Award
Figure 6.9 Grant Analysis: Distribution by Activity Code
Figure 6.10 Word Cloud Analysis: Emerging Focus Areas
Figure 6.11 Grant Analysis: Distribution by Study Section Involved
Figure 6.12 Popular NIH Departments: Distribution by Number of Grants
Figure 6.13 Grant Analysis: Distribution by Type of Recipient Organization
Figure 6.14 Grant Analysis: Prominent Program Officers
Figure 6.15 Popular Recipient Organizations: Distribution by Number of Grants
Figure 6.16 Grant Analysis: Regional Distribution of Recipient Organizations
Figure 7.1. Partnerships and Collaborations: Cumulative Trend by Year, 2016-2020
Figure 7.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3. Partnerships and Collaborations: Distribution by Year and Type of Partnership (2016-2020)
Figure 7.4. Partnerships and Collaborations: Analysis by Year of Partnership and Type of Partner
Figure 7.5. Partnerships and Collaborations: Analysis by Type of Partnership and Type of Partner
Figure 7.6. Partnerships and Collaborations: Most Active Players
Figure 7.7. Partnership and Collaborations: Regional Distribution
Figure 7.8. Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 8.1 Mergers and Acquisitions: Cumulative Year-Wise Trend, 2016-2020
Figure 8.2 Mergers and Acquisitions: Distribution by Type of Agreements (2016-2020)
Figure 8.3 Mergers and Acquisitions: Distribution by Year and Type of Agreements (2016-2020)
Figure 8.4 Mergers and Acquisitions: Continent-wise Distribution
Figure 8.5 Mergers and Acquisitions: Intercontinental and Intracontinental Agreements
Figure 8.6 Mergers and Acquisitions: Country-wise Distribution
Figure 8.7 Acquisitions: Distribution by Key Value Drivers
Figure 8.8 Acquisitions: Distribution by Key Value Drivers and Year of Acquisition (2016-2020)
Figure 9.1 Strategies Adopted by Late-Stage Drug Candidates
Figure 9.2 Strategies Adopted for EPIDIOLEX
Figure 9.3 Strategies Adopted for CannEpil
Figure 9.4 Strategies Adopted for Lenabasum
Figure 9.5 Strategies Adopted for CAUMZ
Figure 9.6 Strategies Adopted for CBD Oil
Figure 9.7 Endocannabinoid System Targeting Drug Developers: Popular Development Strategies
Figure 9.8 Drug Development Strategy: Preferred Paths to Market
Figure 10. 1 Global Endocannabinoid System Targeted Therapeutics Market, 2020-2030 (USD Million)
Figure 10. 2 Epidiolex Sales Forecast, 2020-2030 (USD Million)
Figure 10. 3 CannEpil Sales Forecast, 2020-2030 (USD Million)
Figure 10.4 GWP42003-P Sales Forecast, 2021-2030 (USD Million)
Figure 10.5 Lenabasum Sales Forecast, 2022-2030 (USD Million)
Figure 10.6 PPP011 Sales Forecast, 2022-2030 (USD Million)
Figure 10. 6 PPP011 (Caumz): Target Patient Population
Figure 10.7 Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Target Receptor, 2025 and 2030 (USD Million)
Figure 10.8 Global Endocannabinoid System Targeted Therapeutics Market for CB1 and CB2 Receptor Targeted Therapies, 2021-2030 (USD Million)
Figure 10.9 Global Endocannabinoid System Targeted Therapeutics Market for CB2 Receptor Targeted Therapies, 2022-2030 (USD Million)
Figure 10.10 Global Endocannabinoid System Targeted Therapeutics Market for Other Receptor Targeted Therapies, 2022-2030 (USD Million)
Figure 10. 11 Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Region, 2025 and 2030 (USD Million)
Figure 10. 12 Endocannabinoid System Targeted Therapeutics Market in the US, 2020-2030 (USD Million)
Figure 10. 13 Endocannabinoid System Targeted Therapeutics Market in the UK, 2020-2030 (USD Million)
Figure 10. 14 Endocannabinoid System Targeted Therapeutics Market in Germany, 2020-2030 (USD Million)
Figure 10. 15 Endocannabinoid System Targeted Therapeutics Market in France, 2020-2030 (USD Million)
Figure 10. 16 Endocannabinoid System Targeted Therapeutics Market in Italy, 2020-2030 (USD Million)
Figure 10. 17 Endocannabinoid System Targeted Therapeutics Market in Spain, 2020-2030 (USD Million)
Figure 10. 18 Endocannabinoid System Targeted Therapeutics Market in Japan, 2022-2030 (USD Million)
Figure 10. 19 Endocannabinoid System Targeted Therapeutics Market in Australia, 2020-2030 (USD Million)
Figure 10. 20 Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Target Therapeutic Area, 2025 and 2030 (USD Million)
Figure 10. 21 Global Endocannabinoid System Targeted Therapeutics Market for Autoimmune Diseases, 2020-2030 (USD Million)
Figure 10. 22 Global Endocannabinoid System Targeted Therapeutics Market for Cancer, 2020-2030 (USD Million)
Figure 10. 23 Global Endocannabinoid System Targeted Therapeutics Market for Inflammatory Diseases, 2020-2030 (USD Million)
Figure 10. 24 Global Endocannabinoid System Targeted Therapeutics Market for Genetic Disorders, 2020-2030 (USD Million)
Figure 10.25 Global Endocannabinoid System Targeted Therapeutics Market for Neurological Disorders, 2020-2030 (USD Million)
Figure 10. 26 Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Route of Administration, 2025 and 2030 (USD Million)
Figure 10. 27 Global Endocannabinoid System Targeted Therapeutics Market for Oral Therapies, 2020-2030 (USD Million)
Figure 10.28 Global Endocannabinoid System Targeted Therapeutics Market for Inhalation Therapies, 2022-2030 (USD Million)
Table 4.1 Drugs Targeting Endocannabinoid System: Marketed and Development Pipeline
Table 4.2 Endocannabinoid System Targeted Therapeutics: List of Therapy Developers
Table 5.1 Endocannabinoid Targeting Therapeutics: List of Profiled Companies
Table 5.2 GW Pharmaceuticals: Company Snapshot
Table 5.3 Drug Profile: Marketed / Clinical-stage Candidates
Table 5.4 GW Pharmaceuticals: Recent Developments and Future Outlook
Table 5.5 Corbus Pharmaceuticals: Company Snapshot
Table 5.6 Drug Profile: Marketed / Clinical-stage Candidates
Table 5.7 Drug Profile: Pre-clinical-stage Candidates
Table 5.8 Corbus Pharmaceuticals: Recent Developments and Future Outlook
Table 5.9 Tilray: Company Snapshot
Table 5.10 Drug Profile: Marketed / Clinical-stage Candidates
Table 5.11 Tilray: Recent Developments and Future Outlook
Table 5.12 Tetra Bio-Pharma: Company Snapshot
Table 5.13 Drug Profile: Marketed / Clinical-stage Candidates
Table 5.14 Tetra Bio-Pharma: Future Outlook
Table 5.15 Botanix Pharmaceuticals: Company Snapshot
Table 5.16 Drug Profile: Marketed / Clinical-stage Candidates
Table 5.17 Drug Profile: Preclinical-stage Candidates
Table 5.18 Botanix Pharmaceuticals: Future Outlook
Table 5.19 Kalytera Therapeutics: Company Snapshot
Table 5.20 Drug Profile: Marketed / Clinical-stage Candidates
Table 5.21 Drug Profile: Preclinical-stage Candidates
Table 5.22 Kalytera Therapeutics: Future Outlook
Table 5.23 Therapix Biosciences: Company Snapshot
Table 5.24 Drug Profile: Marketed / Clinical-stage Candidates
Table 5.25 Drug Profile: Pre-clinical-stage Candidates
Table 5.26 Therapix Biosciences: Future Outlook
Table 5.27 Avicanna: Company Snapshot
Table 5.28 Drug Profile: Marketed / Clinical-stage Candidates
Table 5.29 Drug Profile: Preclinical-stage Candidates
Table 5.30 Avicanna: Future Outlook
Table 5.31 GBSciences: Company Snapshot
Table 5.32 Drug Profile: Preclinical Candidates
Table 5.33 GBSciences: Future Outlook
Table 5.34 Echo Pharmaceuticals: Company Snapshot
Table 5.35 Drug Profile: Marketed / Clinical-stage Candidates
Table 5.36 Drug Profile: Preclinical-stage Candidates
Table 7.1 Endocannabinoid System Targeted Therapeutics: Partnerships and Collaborations, 2016-2020
Table 8.1 Endocannabinoid System Targeted Therapeutics: List of Mergers and Acquisitions, 2016-2020
Table 8.2 Acquisitions: Key Value Drivers
Table 10.1 Endocannabinoid System Targeted Therapeutics: List of Forecasted Candidates
Table 10.2 Epidiolex: Target Patient Population (Million)
Table 10.3 CannEpil: Target Patient Population (Million)
Table 10.4 GWP42003-P: Target Patient Population (Million)
Table 10.5 Lenabasum: Target Patient Population (Million)
Table 10.6 PPP011: Target Patient Population (Million)
Table 11.1 Endocannabinoid System Targeted Therapeutics: Summary of the Competitive Insights
Table 12.1 Echo Pharmaceuticals: Key Highlights
Table 12.2 GB Sciences: Key Highlights
Table 12.3 iX Biopharma: Key Highlights
Table 12.4 Tetra Bio-Pharma: Key Highlights
Table 12.5 Vireo Health: Key Highlights
Table 12.6 Zelira Therapeutics: Key Highlights
Table 13.1 Endocannabinoid System Targeted Therapeutics: Distribution by Phase of Development
Table 13.2 Endocannabinoid System Targeted Therapeutics: Distribution by Target Therapeutic Area
Table 13.3 Endocannabinoid System Targeted Therapeutics: Distribution by Route of Administration
Table 13.4 Endocannabinoid System Targeted Therapeutics: Distribution by Dosing Frequency
Table 13.5 Endocannabinoid System Targeted Therapeutics: Distribution by Target Receptor
Table 13.6 Endocannabinoid System Targeted Therapeutics Developers: Distribution by Year of Establishment
Table 13.7 Endocannabinoid System Targeted Therapeutics Developers: Analysis by Number of Pipeline Therapies
Table 13.8 Endocannabinoid System Targeted Therapeutics Developers: Distribution by Company Size and Geographical Location
Table 13.9 GW Pharmaceuticals: Annual Revenues, 2015-2019 (USD Million)
Table 13.10 Tilray: Annual Revenues, 2016-2019 (USD Million)
Table 13.11 Avicanna: Annual Revenues, 2017- 9M 2019 (USD Million)
Table 13.12 GB Sciences: Annual Revenues, 2018 and 2019 (USD Million)
Table 13.13 Grant Analysis: Cumulative Trend by Year of Award, 2016-2020
Table 13.14 Grant Analysis: Distribution by Funding Institute Center
Table 13.15 Grant Analysis: Distribution by Support Period
Table 13.16 Grant Analysis: Distribution by Type of Grant Application
Table 13.17 Grant Analysis: Distribution by Purpose of Grant Award
Table 13.18 Grant Analysis: Distribution by Activity Code
Table 13.19 Grant Analysis: Distribution by Study Section Involved
Table 13.20 Popular NIH Departments: Distribution by Number of Grants
Table 13.21 Grant Analysis: Distribution by Type of Recipient Organization
Table 13.22 Grant Analysis: Prominent Program Officers
Table 13.23 Popular Recipient Organizations: Distribution by Number of Grants
Table 13.24 Partnerships and Collaborations: Cumulative Trend by Year, 2016-2020
Table 13.25 Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.26 Partnerships and Collaborations: Distribution by Year and Type of Partnership (2016-2020)
Table 13.27 Partnerships and Collaborations: Analysis by Year of Partnership and Type of Partner
Table 13.28 Partnerships and Collaborations: Partnerships and Collaborations: Analysis by Type of Partnership and Type of Partner
Table 13.29 Partnerships and Collaborations: Most Active Players
Table 13.30 Partnership and Collaborations: Regional Distribution
Table 13.31 Mergers and Acquisitions: Cumulative Year-Wise Trend (2016-2020)
Table 13.32 Mergers and Acquisitions: Distribution by Type of Agreement (2016-2020)
Table 13.33 Mergers and Acquisitions: Distribution by Year and Type of Agreement (2016-2020)
Table 13.34 Mergers and Acquisitions: Continent-wise Distribution
Table 13.35 Mergers and Acquisitions: Country-wise Distribution
Table 13.36 Acquisitions: Distribution by Key Value Drivers
Table 13.37 Acquisitions: Distribution by Key Value Drivers and Year of Acquisition (2016-2020)
Table 13.38 Global Endocannabinoid System Targeted Therapeutics Market, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.39 EPIDIOLEX: Sales Forecast, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.40 CannEpil: Sales Forecast, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.41 GWP42003-P: Sales Forecast, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.42 Lenabasum: Sales Forecast, 2022-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.43 PPP011: Sales Forecast, 2022-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.44 Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Target Receptor, 2025 and 2030 (USD Million)
Table 13.45 Global Endocannabinoid System Targeted Therapeutics Market for CB1 and CB2 Receptor Targeted Therapies, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.46 Global Endocannabinoid System Targeted Therapeutics Market for CB2 Receptor Targeted Therapies, 2022-2030 (USD Million)
Table 13.47 Global Endocannabinoid System Targeted Therapeutics Market for Other Receptor Targeted Therapies, 2022-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.48 Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Region, 2025 and 2030 (USD Million)
Table 13.49 Endocannabinoid System Targeted Therapeutics Market in the US, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.50 Endocannabinoid System Targeted Therapeutics Market in the UK, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.51 Endocannabinoid System Targeted Therapeutics Market in Germany, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.52 Endocannabinoid System Targeted Therapeutics Market in France, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.53 Endocannabinoid System Targeted Therapeutics Market in Italy, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.54 Endocannabinoid System Targeted Therapeutics Market in Spain, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.55 Endocannabinoid System Targeted Therapeutics Market in Japan, 2022-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.56 Endocannabinoid System Targeted Therapeutics Market in Australia, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.57 Endocannabinoid System Targeted Therapeutics Market: Distribution by Target Therapeutic Area, 2025 and 2030 (USD Million)
Table 13.58 Global Endocannabinoid System Targeted Therapeutics Market for Autoimmune Diseases, 2022-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.59 Global Endocannabinoid System Targeted Therapeutics Market for Cancer, 2022-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.60 Global Endocannabinoid System Targeted Therapeutics Market for Inflammatory Disorders, 2022-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.61 Global Endocannabinoid System Targeted Therapeutics Market for Genetic Disorders, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.62 Global Endocannabinoid System Targeted Therapeutics Market for Neurological Disorders, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.63 Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Route of Administration, 2025 and 2030 (USD Million)
Table 13.64 Global Endocannabinoid System Targeted Therapeutics Market for Oral Therapies, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.65 Global Endocannabinoid System Targeted Therapeutics Market for Inhalation Therapies, 2022-2030: Conservative, Base and Optimistic Scenarios (USD Million)
The following companies and organizations have been mentioned in the report:
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES